In 2004, GTC licensed its IP to Nexia for the biodefense product, Protexia (#msg-4107224). Protexia is now owned by PharmAthene (who since merged with SIGA: #msg-11540838).
GTC could some day realize a small royalty stream from this.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”